Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine

Anil K. Malhotra, Caleb M. Adler, Sasha D. Kennison, Igor Elman, David Pickar, Alan Breier

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

Several lines of evidence suggest that the glutamatergic N-methyl-D- aspartate (NMDA) receptor is involved in the antipsychotic efficacy of the atypical antipsychotic agent clozapine. Clinical data on the interaction between clozapine's mechanism of action and NMDA receptor function have been lacking secondary to a paucity of pharmacologic probes of the NMDA system. We have utilized a double-blind, placebo-controlled infusion paradigm with subanesthetic doses of the NMDA antagonist ketamine to test the hypothesis that clozapine would blunt ketamine-induced psychotic symptoms in schizophrenic patients. Ten schizophrenic patients underwent ketamine infusions while antipsychotic drug free and also during treatment with clozapine. Antipsychotic drug-free patients experienced increases in ratings of positive and negative symptoms. Clozapine treatment significantly blunted the ketamine-induced increase in positive symptoms. These data suggest that NMDA receptor function may be involved in the unique antipsychotic efficacy of clozapine.

Original languageEnglish (US)
Pages (from-to)664-668
Number of pages5
JournalBiological Psychiatry
Volume42
Issue number8
DOIs
StatePublished - Oct 15 1997
Externally publishedYes

Fingerprint

Clozapine
Ketamine
N-Methylaspartate
Psychotic Disorders
Antipsychotic Agents
N-Methyl-D-Aspartate Receptors
Placebos
Therapeutics

Keywords

  • Atypical antipsychotic
  • Clozapine
  • Ketamine
  • N-methyl-D- aspartate
  • Psychosis
  • Schizophrenia

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis : A study with ketamine. / Malhotra, Anil K.; Adler, Caleb M.; Kennison, Sasha D.; Elman, Igor; Pickar, David; Breier, Alan.

In: Biological Psychiatry, Vol. 42, No. 8, 15.10.1997, p. 664-668.

Research output: Contribution to journalArticle

Malhotra, Anil K. ; Adler, Caleb M. ; Kennison, Sasha D. ; Elman, Igor ; Pickar, David ; Breier, Alan. / Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis : A study with ketamine. In: Biological Psychiatry. 1997 ; Vol. 42, No. 8. pp. 664-668.
@article{912d374d2e554deca69fcf1063b2ae5c,
title = "Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine",
abstract = "Several lines of evidence suggest that the glutamatergic N-methyl-D- aspartate (NMDA) receptor is involved in the antipsychotic efficacy of the atypical antipsychotic agent clozapine. Clinical data on the interaction between clozapine's mechanism of action and NMDA receptor function have been lacking secondary to a paucity of pharmacologic probes of the NMDA system. We have utilized a double-blind, placebo-controlled infusion paradigm with subanesthetic doses of the NMDA antagonist ketamine to test the hypothesis that clozapine would blunt ketamine-induced psychotic symptoms in schizophrenic patients. Ten schizophrenic patients underwent ketamine infusions while antipsychotic drug free and also during treatment with clozapine. Antipsychotic drug-free patients experienced increases in ratings of positive and negative symptoms. Clozapine treatment significantly blunted the ketamine-induced increase in positive symptoms. These data suggest that NMDA receptor function may be involved in the unique antipsychotic efficacy of clozapine.",
keywords = "Atypical antipsychotic, Clozapine, Ketamine, N-methyl-D- aspartate, Psychosis, Schizophrenia",
author = "Malhotra, {Anil K.} and Adler, {Caleb M.} and Kennison, {Sasha D.} and Igor Elman and David Pickar and Alan Breier",
year = "1997",
month = "10",
day = "15",
doi = "10.1016/S0006-3223(96)00546-X",
language = "English (US)",
volume = "42",
pages = "664--668",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "8",

}

TY - JOUR

T1 - Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis

T2 - A study with ketamine

AU - Malhotra, Anil K.

AU - Adler, Caleb M.

AU - Kennison, Sasha D.

AU - Elman, Igor

AU - Pickar, David

AU - Breier, Alan

PY - 1997/10/15

Y1 - 1997/10/15

N2 - Several lines of evidence suggest that the glutamatergic N-methyl-D- aspartate (NMDA) receptor is involved in the antipsychotic efficacy of the atypical antipsychotic agent clozapine. Clinical data on the interaction between clozapine's mechanism of action and NMDA receptor function have been lacking secondary to a paucity of pharmacologic probes of the NMDA system. We have utilized a double-blind, placebo-controlled infusion paradigm with subanesthetic doses of the NMDA antagonist ketamine to test the hypothesis that clozapine would blunt ketamine-induced psychotic symptoms in schizophrenic patients. Ten schizophrenic patients underwent ketamine infusions while antipsychotic drug free and also during treatment with clozapine. Antipsychotic drug-free patients experienced increases in ratings of positive and negative symptoms. Clozapine treatment significantly blunted the ketamine-induced increase in positive symptoms. These data suggest that NMDA receptor function may be involved in the unique antipsychotic efficacy of clozapine.

AB - Several lines of evidence suggest that the glutamatergic N-methyl-D- aspartate (NMDA) receptor is involved in the antipsychotic efficacy of the atypical antipsychotic agent clozapine. Clinical data on the interaction between clozapine's mechanism of action and NMDA receptor function have been lacking secondary to a paucity of pharmacologic probes of the NMDA system. We have utilized a double-blind, placebo-controlled infusion paradigm with subanesthetic doses of the NMDA antagonist ketamine to test the hypothesis that clozapine would blunt ketamine-induced psychotic symptoms in schizophrenic patients. Ten schizophrenic patients underwent ketamine infusions while antipsychotic drug free and also during treatment with clozapine. Antipsychotic drug-free patients experienced increases in ratings of positive and negative symptoms. Clozapine treatment significantly blunted the ketamine-induced increase in positive symptoms. These data suggest that NMDA receptor function may be involved in the unique antipsychotic efficacy of clozapine.

KW - Atypical antipsychotic

KW - Clozapine

KW - Ketamine

KW - N-methyl-D- aspartate

KW - Psychosis

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0030861444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030861444&partnerID=8YFLogxK

U2 - 10.1016/S0006-3223(96)00546-X

DO - 10.1016/S0006-3223(96)00546-X

M3 - Article

C2 - 9325559

AN - SCOPUS:0030861444

VL - 42

SP - 664

EP - 668

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 8

ER -